Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-718 in MAGE-A3/A6+ Advanced Cancers
NCT03139370Phase 1Terminated
- Sponsor
- Kite Pharma
- Start
- Dec 2017
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KITE-718 in solid tumor and multiple myeloma (MM), sponsored by Kite Pharma. Primary endpoints: Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities at 21 days and Objective Response Rate at 5 years. Started Dec 2017; status: terminated.
02
Drugs
KITE-718
03
Conditions
solid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT03139370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139370.